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BACKGROUND & AIMS: Infections are common in patients
with severe alcoholic hepatitis (SAH), but little information is
available on how to predict their development or their effects
on patients. Prednisolone is advocated for treatment of SAH,
but can increase susceptibility to infection. We compared the
effects of infection on clinical outcomes of patients treated with
and without prednisolone, and identified risk factors for
development of infection in SAH. METHODS: We analyzed data
from 1092 patients enrolled in a double-blind placebo-
controlled trial to evaluate the efficacy of treatment with
prednisolone (40 mg daily) or pentoxifylline (400 mg 3 times
each day) in patients with SAH. The 2  2 factorial design led to
547 patients receiving prednisolone; 546 were treated with
pentoxifylline. The trial was conducted in the United Kingdom
from January 2011 through February 2014. Data on develop-
ment of infection were collected at evaluations performed at
screening, baseline, weekly during admission, on discharge, and
after 90 days. Patients were diagnosed with infection based on
published clinical and microbiologic criteria. Risk factors for
development of infection and effects on 90-day mortality were
evaluated separately in patients treated with prednisolone (n ¼
547) and patients not treated with prednisolone (n ¼ 545)
using logistic regression. Pretreatment blood levels of bacterial
DNA (bDNA) were measured in 731 patients. RESULTS: Of the
1092 patients in the study, 135 had an infection at baseline,
251 developed infections during treatment, and 89 patients
developed an infection after treatment. There was no associa-
tion between pentoxifylline therapy and the risk of serious
infection (P ¼ .084), infection during treatment (P ¼ .20), or
infection after treatment (P ¼ .27). Infections classified as
serious were more frequent in patients treated with prednis-
olone (odds ratio [OR], 1.27; 95% confidence interval [CI],
1.272.92; P ¼ .002). There was no association betweenprednisolone therapy and infection during treatment (OR, 1.04;
95% CI, 0.781.37; P ¼ .80). However, a higher proportion
(10%) of patients receiving prednisolone developed an infec-
tion after treatment than of patients not given prednisolone
(6%) (OR, 1.70; 95% CI, 1.072.69; P ¼ .024). Development of
infection was associated with increased 90-day mortality in
patients with SAH treated with prednisolone, independent of
model for end-stage liver disease or Lille score (OR, 2.46; 95%
CI, 1.414.30; P ¼ .002). High circulating bDNA predicted
infection that developed within 7 days of prednisolone therapy,
independent of Model for End-Stage Liver Disease and white
blood cell count (OR, 4.68; 95% CI, 1.8012.17; P ¼ .001). In
patients who did not receive prednisolone, infection was not
independently associated with 90-day mortality (OR, 0.94; 95%
CI, 0.541.62; P ¼ .82) or levels of bDNA (OR, 0.83; 95% CI,
0.391.75; P ¼ .62). CONCLUSIONS: Patients with SAH given
prednisolone are at greater risk for developing serious
infections and infections after treatment than patients not
given prednisolone, which may offset its therapeutic benefit.
Level of circulating bDNA before treatment could identify
patients at high risk of infection if given prednisolone; these
data could be used to select therapies for patients with SAH.
EudraCT no: 2009-013897-42; Current Controlled Trials no:
ISRCTN88782125.Keywords: STOPAH Trial; MELD; E coli; Steroid.
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liver failure after prolonged, heavy alcohol misuse. Severe
cases are defined by the Maddrey’s discriminant function
(DF), a calculation utilizing the serum bilirubin and pro-
thrombin time. Where DF is 32, ninety-day mortality is
30%40%; below this threshold spontaneous survival is
>95%.1–3 In common with other forms of liver failure, SAH
is associated with increased susceptibility to infection. In
the context of SAH, it has been reported that 13%–25% of
patients have an infection at presentation and a similar
proportion develop an infection during treatment.3,4
Current guidelines recommend the use of prednisolone,
a corticosteroid with broad anti-inflammatory and immu-
nosuppressive actions for the management of SAH, although
few studies have shown benefit beyond 28 days.5–7 In the
Steroids or Pentoxyfilline for Alcoholic Hepatitis (STOPAH)
trial, prednisolone almost doubled the risk of infections
reported as serious adverse events (13% vs 7%, which was
significant at the P ¼ .002 level). However, the relationships
between prednisolone and liver function, infection, and
mortality remain contentious.4,8
The aim of this study was to characterize the incidence
and impact of infection in SAH using the data from the large
cohort of patients recruited to the multicenter STOPAH trial.
In addition, this study evaluates pretreatment circulating
levels of 16S ribosomal bacterial DNA (bDNA) as a predictor
of the subsequent development of infection in patients
treated with and without prednisolone by random
double-blind allocation.
Materials and Methods
Study Population
Patients were recruited in accordance with the STOPAH
trial protocol.9 All had a history of alcohol misuse; compatible
clinical, laboratory, and/or liver biopsy features of alcoholic
hepatitis; no other identified causes of liver disease; and
DF 32. Infections, if present, were treated and controlled with
antibiotics before enrolment. All participants, or their legally
appointed representative, provided written informed consent.
The trial was approved by the Multicenter Research Ethics
Committee (reference 09/MRE09/59) and conducted in
accordance with the Medicines for Human Use (Clinical Trials)
Regulations 2004 (2006 amendment); the European Union
Clinical Trials Directive (Directive 2001/20/EC) guidelines; the
principles of the International Conference on Harmonization
Good Clinical Practice and under the oversight of University of
Southampton Clinical Trials Unit. All participants, or their le-
gally appointed representative, provided written informed
consent. All authors had access to the study data and have
reviewed and approved the final manuscript.
Group Allocation
STOPAH utilized a double-blind, double-dummy, 2  2
factorial design.9 Patients were randomized to treatment with
40 mg prednisolone once a day or 400 mg pentoxyfilline 3
times a day, neither, or both. There was no mortality benefit
from pentoxyfilline, but a possible 28-day mortality benefitfrom prednisolone.10 The effect of prednisolone on infection
was examined by comparing 2 groups: prednisolone (n ¼ 547)
and no-prednisolonetreated patients (n ¼ 545).
Mortality Data
Data regarding date and cause of death were collected
during the follow-up period. Patients were also consented for
follow-up via the National Health Service Information Centre
Data Linkage service, ensuring that if they were lost to follow-
up and died, this information could be captured. Mortality at 90
days was analyzed in order to capture the occurrence and
impact of all infections occurring during or after the treatment
period.
Periods of Infection and Antibiotic Treatment
Clinical data regarding the development of infection were
collected at trial visits that occurred at screening, baseline,
weekly during admission, on discharge and at 90 days. Data
regarding the development of infection submitted in reports of
serious adverse events (SAEs) were also incorporated. The
diagnosis of infection was made prospectively by treating
physicians who were blind to treatment allocation with or
without prednisolone. Diagnosis was guided by criteria for
infection in the setting of liver disease outlined by Bajaj et al.11
Baseline infections were defined as those that occurred
between admission and the start of therapy. Active antibiotic
treatment at the start of trial therapy was defined as intrave-
nous antibiotics commenced and continued within 5 days prior
to treatment start date. Incident infections were defined as
those that occurred after the start of treatment—these were
further broken down into 3 categories relevant to the clinical
management of these patients:
1. Day 7 infections occurred within the first 7 days of
therapy (aligned with liver function data available at 7
days from which Lille score was calculated);
2. On-treatment infections within the study treatment
period (28 days);
3. Post-treatment infections occurring in the day 28 to day
90 follow-up period;Bacterial DNA Measurement
An EDTA blood sample was taken from patients at enrol-
ment. DNA extraction was performed on 400 mL blood using
Qiagen (Hilden, Germany) QIAamp DNA Mini kits under aseptic
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mined and measured by real-time polymerase chain reaction
(PCR). There are no established cut-off values that define
positive from negative bDNA values. In this study, bDNA level
that had 80% specificity for predicting the subsequent devel-
opment of infection in prednisolone-treated patients within 7
days (18.5 pg/mL) was considered a high bDNA level (hibDNA)
for subsequent modeling analyses.
The PCR methodology was adapted from that reported pre-
viously.12 Briefly, primers directed against the V7V9 variable
region of the 16S gene (forward: RW01; 50->30 sequence
AACTGGAGGAAGGTGGGGAT, reverse: DG74.R; 50->30 sequence
AGGAGGTGATCCAACCGCA) were combined with a custom
fluorescent probe (6-FAM- TACAAGGCCCGGGAACGTATTCACCG-
TAMRA; Life Technologies, Carlsbad, CA) at final concentrations
of 0.5 mM and 0.25 mM, respectively. This was combined with 10
mL Taqman Gene Expression mix (Applied Biosciences, Foster
City, CA), 4 mL extracted DNA and PCR-grade water, to give a
final reaction volume of 20 mL. PCR was performed on a Ste-
pOne Plus PCR machine (Applied Biosciences) with hot-start
activation (2 minutes at 50C, 10 minutes at 95C) and 40 re-
action cycles (15 seconds at 95C, 30 seconds at 60C and 60
seconds at 72C to collect fluorescence). Serial 10-fold dilutions
of Escherichia coli DNA (0.08 ng/mL to 0.000008 ng/mL) and a
negative control were run to generate a standard curve. Stan-
dards and samples were run in triplicate. Any sample displaying
a positive signal at or below the level of the negative control
was considered negative. Any triplicate group with readings >1
copy cycle apart was considered unreliable and discarded;
otherwise, the mean reading was calculated. Standard curves
were generated and concentrations interpolated in Prism,
version 7.0 (GraphPad, La Jolla, CA). bDNA levels are given as
picograms bDNA per milliliter of whole blood from which it was
extracted.
Statistical Analysis
Statistical analyses were conducted in SPSS, version 23
(IBM, Armonk, NY) and survival curves were drawn using R
(Vienna, Austria). Comparisons between groups were tested
using either MannWhitney U test for nonparametrically
distributed continuous variables or c2 test for proportions.
Associations between explanatory variables and end points
were tested using logistic regression. Early improvement in
liver function was defined as Lille score <.45.13
In light of previously published data regarding the rela-
tionship between prednisolone and early improvement in liver
function, infection, and mortality,4 we tested, a priori, for an
interaction between these factors and the end points under
consideration by logistic regression.
Previous studies have confirmed that infection and mor-
tality, if present, are positively associated.4,8 In view of this,
and the biologic implausibility that infection could be associ-
ated with reduced mortality, a one-tailed test of association
between bDNA and 90-day mortality in prednisolone-treated
patients was performed. Secondary outcomes were tested
post hoc and are not corrected for multiple testing because
they are exploratory. For analyses that modeled the expected
90-day mortality in patients with high bDNA treated with or
without prednisolone, matching was performed using the
FUZZY extension within SPSS, specifying tolerance of 2 pg/mL
bDNA.Results
Population Characteristics
Data regarding infection were available in 1092 of 1103
(99%) of patients randomized in the STOPAH trial; baseline
characteristics are presented in Table 1.
Baseline Infection
Infection at baseline occurred in 12% (135 of 1092) of
patients (Supplementary Table 1). Chest infections were the
single largest category, accounting for 34% (42 of 125) of
infections that specified a site of origin (Supplementary
Table 2). Positive microbiological cultures were reported
in 56 of 135 (41%) patients. E coli was the most commonly
isolated organism (12 of 40 [30%]; Supplementary Table 3).
Between admission and initiation of trial therapy, 492 of
1092 (45%) patients were prescribed an antibiotic. Of those
patients, 293 (60%) continued to receive antibiotic therapy
into the treatment period.
Overall, there was no statistically significant association
between baseline infection and mortality at 90 days (31%
vs 26%; odds ratio [OR], 1.31; 95% confidence interval [CI],
0.881.94; P ¼ .18; Figure 1A). In patients with baseline
infection who did not receive prednisolone, active antibiotic
therapy when starting treatment had no impact on mortality
(30% vs 32%; P ¼ .81; Figure 1B). However, in those who
received prednisolone, there was a significant reduction in
90-day mortality associated with continued antibiotic ther-
apy when compared with those patients in whom antibiotic
therapy was stopped before initiating prednisolone (13% vs
52%; OR, 0.13; 95% CI, 0.0380.47; P ¼ .002; Figure 1C).
Incident Infection
On-treatment infections were diagnosed in 251 patients
(23%) and post-treatment infections were seen in 89 pa-
tients (Supplementary Table 1). The most common site of
infection in both cases was chest (37% [110 of 301] and
39% [40 of 102], respectively). On-treatment infection was
significantly associated with recurrent post-treatment
infection risk (OR, 1.93; 95% CI, 1.213.06; P ¼ .005).
Taken together positive cultures were reported in 147 of
372 episodes of incident infection (40%). E coli was the
most frequently cultured organism (33 of 133 [25%];
Supplementary Table 3). In patients developing incident
infection, median time to develop the infection was 13 days
after the start of treatment.
Univariable factors associated with the development of
incident infection are given in Table 2. On multivariable anal-
ysis, an independent effect was demonstrated for peripheral
white cell count (OR, 1.04; 95% CI, 1.021.07; P ¼ .002) and
age (OR, 1.02; 95% CI, 1.001.03; P ¼ .01). Baseline DF and
Model for End-Stage Liver Disease (MELD) scores were both
strongly associated with the subsequent risk of developing an
infection (P ¼ .002 and P < .001, respectively; Table 2).
Treatment and Infection Risk
Serious infections (SAEs), on-treatment infections, and
post-treatment infections were considered separately when
Table 1.Baseline Characteristics of Study Population
Variable All patients
Baseline infection only
(n ¼ 94)
Baseline and incident infection
(n ¼ 41)
Incident infection only
(n ¼ 268)
Never infected
(n ¼ 689)
Age, y 48.8 (41.956.3) 49.5 (41.954.7) 47.1 (41.156.9) 50.3 (42.658.8) 48.3 (41.855.8)
Sex, male, n (%) 685 (62.7) 60 (63.8) 26 (63.4) 159 (59.3) 440 (63.9)
Alcohol consumption, U/wk 132 (84210) 125 (80197) 184 (96249) 120 (80199) 128 (84210)
Prednisolone, n (%) 547 (50) 44 (47) 20 (49) 144 (54) 339 (49)
Systolic blood pressure, mm Hg 110 (102120) 112 (105121) 113 (100126) 110 (100120) 110 (102120)
Diastolic blood pressure, mm Hg 90 (6074) 69 (6077) 66 (5877) 65 (6073) 68 (6075)
Pulse, beats/min 90 (8098) 82 (8898) 95 (77102) 91 (80100) 89 (8098)
Temperature, C 36.8 (36.537.1) 36.8 (36.637.1) 36.8 (36.437.3) 36.8 (36.537.1) 36.8 (36.537.1)
Hemoglobin, g/L 107 (94120) 102 (90114) 100 (88118) 105 (94120) 108 (95121)
Total white cell count, 103 per mm3 9.00 (6.2312.6) 9.90 (6.6814.4) 10.6 (7.0516.1) 10.1 (7.113.7) 8.20 (6.0011.9)
Neutrophils, 103 per mm3 6.2 (4.19.8) 7.2 (4.211.6) 6.9 (5.413.3) 7.3 (4.911.0) 5.7 (3.99.0)
International normalized ratio 1.80 (1.562.09) 1.91 (1.602.32) 1.74 (1.582.00) 1.82 (1.602.12) 1.70 (1.512.00)
Albumin, g/L 25 (2129) 26 (2231) 25 (1831) 24 (2028) 25 (2129)
Bilirubin, mg/dL 16.1 (10.124.4) 14.7 (9.4724.4) 18.6 (9.625.7) 16.7 (10.625.1) 15.9 (9.9024.0)
Alanine transaminase, IU/L 43 (3061) 38 (2751) 39 (3161) 44 (2864_ 43 (3162)
Aspartate transaminase, IU/L 124 (87169) 125 (89148) 120 (90164) 122 (87178) 125 (87171)
Sodium, mmol/L 134 (130136) 134 (131138) 134 (130137) 133 (130136) 134 (130137)
Urea, mmol/L 3.3 (2.25.2) 3.5 (2.46.7) 4.3 (2.67.1) 3.6 (2.25.4) 3.1 (2.24.9)
Creatinine, mg/dL 0.72 (0.600.97) 0.72 (0.590.99) 0.75 (0.621.03) 0.76 (0.601.06) 0.72 (0.600.92)
Discriminant functiona 55.4 (43.173.7) 62.1 (46.686.7) 56.9 (47.068.4) 60.6 (45.582.0) 53.4 (42.169.8)
Model for End-Stage Liver Diseaseb 23.4 (21.026.4) 24.4 (21.728.6) 24.3 (21.727.0) 24.2 (21.428.1) 22.9 (20.825.7)
NOTE. Groupings are based on the entire study population, with subgroups of when the infection was diagnosed relative to the start of treatment. Baseline infection was
defined as those that occurred between admission and the start of therapy. Incident infections were those that occurred after initiation of therapy. Data are presented
median (interquartile range) unless otherwise indicated.
aDiscriminant function ¼ 4.6  (PTPatient  PTControl [seconds]) þ bilirubin [mg/dL].
bModel for End-Stage Liver Disease ¼ 3.78  ln[serum bilirubin (mg/dL)] þ 11.2  ln[INR] þ 9.57  ln[serum creatinine (mg/dL)] þ 6.43.
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Figure 1. Prescription of
antibiotics significantly
modulates the impact of
baseline infection on 90-
day mortality in
prednisolone-treated pa-
tients. In all patients, no
statistically significant
impact of baseline sepsis
on mortality is seen (A). In
patients who present with
infection and do not
receive prednisolone,
continuation of antibiotics
alongside treatment for AH
does not impact upon
mortality (B), however, in
patients who receive
prednisolone concurrent
antibiotic therapy signifi-
cantly reduces mortality
(C).
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findings that prednisolone increases the risk of serious and
late infections in particular.3,14Pentoxyfilline
There was no association between pentoxyfilline therapy
and the risk of serious (SAE), on-treatment, or post-
treatment infections (OR, 0.70; 95% CI, 0.461.05;
P ¼ .084; OR, 0.83; 95% CI, 0.631.10; P ¼ .20; and OR,
0.78; 95% CI, 0.501.21; P ¼ .27, respectively).Prednisolone
Infections classified as serious (SAEs) were more
frequent in patients treated with prednisolone (OR, 1.27;
95% CI, 1.272.92; P ¼ .002).3 There was no association
between prednisolone therapy and on-treatment infection
(OR, 1.04; 95% CI, 0.781.37; P ¼ .80). However, prednis-
olone was associated with an increased risk of developing
post-treatment infection (56 of 547 [10%] vs 33 of 545
[6%]; OR, 1.70; 95% CI, 1.072.69; P ¼ .024).
In addition, there were significant interactions between
prednisolone and Lille response in relation to both 90-day
Table 2.Associations Between Baseline Characteristics and the Development of Incident Infection
Variable
Univariable Multivariable
OR (95% CI) P value OR (95% CI) P value
Demographics
Age, y 1.01 (1.001.03) .055 1.02 (1.001.03) .013
Sex, male 1.18 (0.901.55) .220 — —
Alcohol consumption, U/wk 1.00 (0.991.00) .522 — —
Observations
Systolic blood pressure, mm Hg 1.00 (0.991.01) .909 — —
Diastolic blood pressure, mm Hg 0.99 (0.981.00) .098 0.99 (0.981.00) .177
Pulse, beats/min 1.01 (0.991.02) .077 1.01 (1.001.02) .056
Temperature, C 1.06 (0.821.39) .656 — —
Hematology and biochemistry
Hemoglobin, g/L 0.99 (0.991.00) .221 — —
Total WBC, 103 per mm3 1.05 (1.031.08) <.001 1.04 (1.021.07) .002
Neutrophils, 103 per mm3 1.06 (1.031.08) <.001 — —
INR 1.45 (1.121.89) .005 1.31 (0.991.73) .058
Albumin, g/L 0.98 (0.950.99) .031 0.98 (0.961.00) .092
Bilirubin, mg/dL 1.01 (0.991.03) .065 1.00 (0.991.02) .648
Alanine transaminase, IU/L 1.00 (0.991.00) .841 — —
Aspartate transaminase, IU/L 0.99 (0.991.00) .485 — —
Sodium, mmol/L 0.98 (0.951.00) .062 0.99 (0.971.02) .695
Urea, mmol/L 1.03 (0.991.06) .102 — —
Creatinine, mg/dL 1.38 (1.091.75) .009 1.20 (0.911.58) .203
Clinical scores
Discriminant functiona 1.01 (1.001.01) .002 — —
MELDb 1.06 (1.031.09) <.001 — —
NOTE. Variables showing a trend to significance on univariable analysis (P < .10) were entered into multivariable analysis.
INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; WBC, white blood cell count.
aDiscriminant function ¼ 4.6  (PTPatient-PTControl [seconds]) þ bilirubin [mg/dL].
bMELD ¼ 3.78  ln[serum bilirubin (mg/dL)] þ 11.2  ln[INR] þ 9.57  ln[serum creatinine (mg/dL)] þ 6.43
April 2017 Infection in Alcoholic Hepatitis 1073
CL
IN
IC
AL
LI
VE
Rmortality (P ¼ .00017) and infection (P ¼ .045). Conse-
quently, prednisolone and no-prednisolone groups were
considered separately for statistical analyses other than
comparisons between treatment arms.
Development of an incident infection was significantly
associated with mortality in prednisolone-treated patients
(prednisolone: 39% vs 22%; OR, 2.27; 95% CI, 1.523.38;
P < .0001), but was not in the patients who did not receive
prednisolone (31% vs 24%; OR, 1.36; 95% CI, 0.892.08;
P ¼ .15).
Multivariable analysis incorporating terms reflecting
development of infection, baseline severity of liver diseaseTable 3.Multivariable Analysis Examining the Effect of Incident
Liver Function (Model for End-Stage Liver Disease), En
Variable
Prednisolone
OR (95% CI) P
Infection 2.46 (1.414.30)
MELD 1.08 (1.021.15)
Encephalopathy 1.83 (1.023.28)
Lille response .36 (.21.64) <
NOTE. Results are given for both prednisolone-treated and no-
MELD, Model For End-Stage Liver Disease.(MELD), presence of encephalopathy, and response to treat-
ment (Lille score <0.45) was performed. In prednisolone-
treated patients an independent effect of infection on
90-day mortality was seen (OR, 2.46; 95% CI, 1.414.30;
P ¼ .002) (Table 3).Alcohol and Infection Risk
Recidivism after the episode of SAH was recorded at 90
days. Importantly, there was no association between pred-
nisolone treatment and a return to alcohol drinking (P ¼
.95). Further detail is provided in Supplementary Results.Infection on Mortality by Logistic Regression, After Adjusting
cephalopathy, and Treatment Response (Lille Response)
No prednisolone
value OR (95% CI) P value
.002 .94 (.541.62) .82
.012 1.12 (1.061.20) <.001
.042 2.19 (1.243.84) .007
.001 .29 (.16.50) <.001
prednisolone groups.
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Failure to demonstrate an early improvement in liver
function (Lille score >.45) was associated with an increased
risk of infection in prednisolone-treated patients (52% vs
29%; OR, 2.70; 95% CI, 1.694.32; P ¼ .00003), but not in
patients treated without prednisolone (34% vs 29%; OR,
1.28; 95% CI, 0.821.98; P ¼ .28).
Day 7 infections, developing before calculation of the
Lille score at day 7, were associated with a significantly
increased risk of Lille nonresponse in prednisolone-treated
patients (OR, 2.82; 95% CI 1.485.26; P ¼ .002), but not in
patients treated without prednisolone (OR, 1.28; 95% CI,
0.702.34; P ¼ .43). Accordingly, prednisolone treatment
was associated with a significant increase in 90-day mor-
tality in patients who developed infection within 7 days
(59% vs 38%; OR, 2.34; 95% CI, 1.124.88; P ¼ .023)
(Figure 2).Utility of Bacterial DNA Level to Predict Infection
and Mortality
Whole blood samples were available for bDNA analysis
in 68% (740 of 1092) of patients included in the clinical
data analysis. Further detail regarding characteristics of
patients from whom bDNA results were not available is
provided in Supplementary Results.
Ninety percent of SAH patients (661 of 731) had
detectable bDNA from whole blood samples. However, there
was no correlation between age or alcohol consumption and
bDNA (rs < .01, P ¼ .97 and rs ¼ .05, P ¼ .21). There was
also no correlation between baseline bDNA and baseline
liver function as described by MELD, DF, or Glasgow Alco-
holic Hepatitis Score (rs ¼ .04, P ¼ .25; rs ¼ .04, P ¼ .25; and
rs ¼ .04, P ¼ .32, respectively). Clinical characteristics of
patients are presented in Supplementary Table 4 by day 7
infection status.Figure 2. Early-onset
infection leads to excess
mortality in patients
treated with prednisolone.
In patients who do not
develop infection within
the first 7 days, there is a
nonsustained improve-
ment in mortality at 28
days (A). However, in pa-
tients who have early
onset of infection, treat-
ment with prednisolone is
associated with a dramatic
increase in mortality (B).
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reduce bDNA levels, we sought and found an interaction be-
tween bDNA and intravenous antibiotic therapy in the pre-
diction of day 7 infection (P ¼ .02). Patients who had been
treated with intravenous antibiotics within 5 days before
sampling were therefore excluded (195 patients, leaving 536
patients available for further analysis). Patients were further
divided by treatment with prednisolone (prednisolone, n ¼
265; no prednisolone n¼ 271) in line with previous analyses.
There was a striking association between bDNA and
development of infection within 7 days in patients treated
with prednisolone (developed infection vs did not develop
infection: 20.9 vs 8.3 pg/mL [median values]; P ¼ .004).
Area under receiver operating characteristic curve for
prednisolone-treated patients was .704 (95% CI .58.83;
P ¼ .0032). By way of comparison, the area under the
receiver operating characteristic for white blood cell count
to predict infection within 7 days was .577, but this was not
statistically significant (P ¼ .265; Supplementary Table 5).
bDNA level was not associated with day 7 infection in pa-
tients treated without prednisolone (developed infection vs
did not develop infection: 12.7 vs 12.3 pg/mL; P ¼ .95).
A cut-off of 18.5 pg/mL bDNA was 80% specific for
prediction of infection within 7 days. This cut-off was used
to define a high level of bDNA (hibDNA). hibDNA was asso-
ciated with increased risk of infection by day 7 in
prednisolone-treated patients (OR, 4.48; 95% CI,
1.7011.81; P ¼ .002). This association remained signifi-
cant after multivariable analysis that controlled for con-
founding factors of MELD and white blood cell count
(Table 4). In contrast, hibDNA was not associated with the
development of day 7 infection in either univariable or
multivariable analysis for patients treated without
prednisolone (Table 4).
All patients were considered for survival analyses (n ¼
731). bDNA level before treatment correlated with Lille
score (rs ¼ .16; P ¼ .0006), irrespective of antibiotic treat-
ment (rs ¼ .27, P ¼ .003 for antibiotic treated patients and
rs ¼ .12, P ¼ .02 for patients not treated with antibiotics
within 5 days before sampling). In addition, bDNA level was
higher for patients who died by 90 days compared with
those who survived to 90 days (11.2 vs 9.3 pg/mL; P ¼ .04).
hibDNA was associated with 90-day mortality (OR, 1.39;Table 4.Multivariable Logistic Regression Analysis
Incorporating Bacterial DNA, Model for End-Stage
Liver Disease, and White Blood Cell Count for
Prediction of Day 7 Infection in Patients Treated
With and Without Prednisolone
Variable
Prednisolone No prednisolone
OR (95% CI) P value OR (95% CI) P value
hibDNA 4.68 (1.8012.17) .001 0.83 (0.391.75) .62
MELD 1.08 (0.991.17) .097 1.07 (0.991.15) .08
WBC 1.06 (0.971.16) .187 1.07 (0.991.15) .07
MELD, Model for End-Stage Liver Disease; WBC, white blood
cell count.95% CI, .982.0; 29% vs 23% 90-day mortality in patients
with hibDNA vs patients without hibDNA; P ¼ .03).
Finally, the strategy of using hibDNA to exclude use of
prednisolonewasmodeled bymatching hibDNA patients in the
prednisolone-treated group with patients in the
no-prednisolone group. This would estimate the likely mor-
tality at 90 days if these patients had not received predniso-
lone. In patients with hibDNA, avoidance of prednisolone
treatment was associatedwith a reduction in 90-daymortality
(17% vs 29%; OR, 1.96; 95% CI, .844.3; P ¼ .05) (Figure 3).
Discussion
Our analysis of 1092 patients with SAH confirms that
infection is highly prevalent, with 12% having infection at
baseline and 23% of SAH patients developing infection on
treatment. Prednisolone is associated with a significant in-
crease in the risk of serious infections.3 Furthermore, these
data indicate that prednisolone therapy appears to confer an
excess risk of post-treatment infections, irrespective of
severity. Cabre et al14 also described an increased rate of
late infections in patients treated with prednisolone
compared to those treated with enteral nutrition. This
phenomenon might partly explain why early improvements
in liver function attributable to prednisolone did not
translate into a sustained survival benefit.
Although there was no overall association between pre-
sentation with infection and mortality, these data suggest that
baseline infection might not be entirely benign. Decisions
regarding continuation of antibiotic therapy are important
when patients are to receive prednisolone. The current study
suggests that continued antibiotic therapy in patients with
baseline infection confers a survival advantage.Figure 3. Comparison of survival curves to 90 days in pa-
tients with matched and high bDNA levels who were treated
with prednisolone vs no prednisolone.
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LIVERThe impact of infection on 90-day mortality is critically
modulated by prednisolone. In patients treated with pred-
nisolone, infection exerts an independent effect on mortality
by 90 days. When prednisolone is not used, the effect of
infection on 90-day mortality is secondary to baseline liver
impairment and early improvement in liver function. In
other words, patients who are not treated with prednisolone
but who have poor liver function are more likely to develop
infection and die within 90 days. Further, we show that
development of infection before calculation of the Lille score
at day 7 is associated with classification as a Lille nonre-
sponder; this timing raises the possibility that early infec-
tion might modulate Lille score. In patients who developed
infection within the first 7 days, prednisolone dramatically
increased the risk of mortality at 90 days.
Concerns about infectious complications have restricted
use of prednisolone. As a result, strategies that aim to first
test for benefit from prednisolone before continued use
have gained support. One approach is to use the Lille model
after 7 days of prednisolone therapy to determine whether
corticosteroids should be continued or not. However, in a
trial of patients who were Lille nonresponders after 7 days
of corticosteroid therapy, there was no survival benefit
associated with withdrawal of prednisolone and replace-
ment with pentoxyfilline compared with patients who were
treated for the full 28 days with prednisolone.15 We spec-
ulate that 7 days of prednisolone therapy may be enough to
impair host immunity to allow development of serious
infection, and that discontinuation of steroids after 7 days
may be unable to reverse the damage.
Consequently, the ability of pretreatment bDNA levels to
predict the development of infection in patients who were
uninfected at the time of sampling and who subsequently
receive prednisolone is of interest. This strategy differs from
previous studies in which investigators sought to differen-
tiate SAH patients with infection at the time of presentation
from those without,16 and is the first attempt to evaluate
bDNA in the context of corticosteroid immunosuppres-
sion.17 While the area under the receiver operating char-
acteristic for bDNA to predict the subsequent development
of infection was modest in the current study, bDNA was
nonetheless superior to white blood cell count in this re-
gard. Also of interest is the observation that bDNA was not
predictive of infection when patients were not subsequently
treated with prednisolone: only when the immune system
had been modulated by prednisolone and when the circu-
lating bacterial load was high was there a heightened risk of
developing infection. The ability of bDNA to predict infec-
tion before alternative immunosuppressive agents are used
is an enticing prospect that warrants dedicated testing.
bDNA level may also be regarded as a target for therapy
before initiation of immunosuppression. Where culture results
are unavailable but bDNA levels are high, a possible paradigm
could be to repeat microbiological screening and treat with
broad-spectrum antibiotics until bDNA has returned to normal
levels. Randomly allocated empirical broad-spectrum anti-
biotic therapy in SAH is the subject of ongoing clinical trials.18,19
The translocation of bacterial products from gut to portal
vein in heavy alcohol drinkers has been proposed as amechanismofhepatic injury and cause of hepatic inflammation
in SAH.20 Indeed,>90% of SAH patients had detectable bDNA
levels in the current study, which is substantially higher than
rates seen in healthy controls, patients with suspected blood-
stream infections, and patients with other forms of decom-
pensated liver disease.17,21,22 The higher rate of bacteremia
seen in these SAH patients might represent extensive bacterial
translocation23 or defective leukocyte clearance,24–26 or both.
Bacterial translocationhas been implicated in thepathogenesis
of SAH.20,27 However, in the current study, while circulating
bDNA predicted the development of infection, it did not
correlatewithmarkersof baseline liver function such asMELD,
DF, or Glasgow Alcoholic Hepatitis Score.
In common with other studies in the field, the central
limitation of this study is the lack of a gold standard to di-
agnose infection. In our data, only a minority of infections
(40% of incident infections) yielded an organism on micro-
biological culture; most were diagnosed clinically. Clinical
diagnosis of infection will be sensitive but may lack speci-
ficity, with physicians unable to differentiate inflammatory
responses driven by underlying alcoholic hepatitis, from
infection. However, in this regard, we highlight the con-
trasting outcomes of patients diagnosed with infection in this
study in relation to the double-blind allocation of predniso-
lone. The association between randomly allocated predniso-
lone therapy and poor outcomes for this subset of patients
suggests that they had a condition exacerbated by immuno-
suppression, which is very likely to have been infection.
No treatment was shown to reduce 90-day mortality for
SAH in the STOPAH study.3 In the current retrospective
analysis, a reduction in 90-day mortality was estimated by
using pretreatment bDNA level to guide prescription of
prednisolone and was of borderline statistical significance.
Larger prospective randomized studies are needed to defi-
nitely report whether bDNA-guided therapy can impact on
mortality, in SAH, and perhaps in other acute inflammatory
conditions where immunosuppression is required.
In summary, these data show that infections are
frequent in SAH, but are only independently associated with
mortality when patients receive prednisolone. These in-
fections may be predicted by measuring levels of circulating
bacterial DNA, raising the possibility that such infections,
and consequent mortality, could be avoided by bDNA-
stratified prednisolone prescribing for SAH patients.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dxdoi.org/10.1053/
j.gastro.2016.12.019.References
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Supplementary Results
Alcohol and Infection Risk
Drinking data was collected at the day-90 visit time
point. Data regarding drinking behavior are incomplete and
available for 478 patients surviving to complete visit at 90
days. For the purposes of subsequent analysis, drinking
behavior is considered dichotomously as abstinent or
drinking.
There is no association between prednisolone treatment
and a return to drinking (P ¼ .95) in the cohort of patients
with available data. No association is revealed when analysis
is restricted to those completing treatment (survival to day
28) or surviving a minimum of 90 days after the start of
treatment.
No association is revealed between the reported
maximum level of alcohol consumption at baseline and the
development of a serious infection (SAE) (P ¼ .89), on
treatment (P ¼ .11), or post-treatment (P ¼ .20) infection.
There was a trend toward significance for an increased risk
of post-treatment infection associated with a return to
drinking (OR, 1.68; 95% CI, 0.972.91; P ¼ .07). This result
should, however, be interpreted with caution. It is highly
probable that patients who had returned to drinking and
developed an infection were more likely to attend follow-up
than those who had returned to drinking but experienced no
infection. Follow-up visits may, for example, have been
completed opportunistically when patients who had
returned to drinking had attended hospital for assessment
and treatment of their infective complication. Consequently,
the sample of patients who returned to drinking might well
be biased in favor of those who had developed an infection.
Smoking and Infection Risk
Smoking data were available on 986 subjects. A minority
of patients reported never smoking (n ¼ 306 [31%]), while
the remainder were split between active (n ¼ 447 [41%])
and former smokers (n ¼ 233 [21%]).
No statistically significant effect of smoking status
(never, current, former) was found on the occurrence of
chest infections, including when adjusted for prednisolone
treatment (Supplementary Table 6).
Bacterial DNA Analyses
Whole blood samples were available for bDNA analysis
in 68% (740 of 1092) of patients included in the clinical
data analysis. There was insufficient sample available from
the remaining patients (352 of 1092 [32%]) who partici-
pated in the STOPAH study. In an additional 9 patients, the
discrepancy between PCR replicates was >1 copy cycle and
the result deemed invalid. A bDNA result was therefore not
available in 361 of 1092 patients (33%). Incident infection
in patients for whom bDNA was measured was higher than
in patients for whom bDNA was not measured (228 of 731
[31%] vs 81 of 362 [22%]), although the mortality rate
within the population in whom bDNA was measured was
similar to the mortality rate for those in whom bDNA was
not measured (29% [106 of 361]) vs 25% [180 of 731]).
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Supplementary Table 2.Full Breakdown of Infections by Site and Time of Occurrence in Relation to Presentation and
Treatment
Site of infection Baseline infection (n ¼ 141)
Incident infection
On treatment (n ¼ 301) Post-treatment (n ¼ 102)
Respiratory, n (%) 42 (33.6) 110 (36.5) 40 (39.2)
Lower respiratory tract, n 41 108 39
Upper respiratory tract, n 1 2 1
SBP and bacteremia, n (%) 28 (22.4) 75 (24.9) 23 (22.5)
SBP, n 16 47 13
Bacteremia, n 8 28 10
Urinary, n (%) 24 (19.2) 31 (10.3) 10 (9.8)
Other, n (%) 12 (9.6) 46 (15.3) 10 (9.8)
Biliary, n 1 0 0
Intra-abdominal, n 1 6 2
Deep tissue, n 1 4 1
Gastrointestinal, n 3 9 3
Skin and soft tissue, n 6 25 2
Orodontal, n 0 2 0
ENT, n 0 0 2
Unknown, n (%) 19 (15.2) 36 (12.0) 18 (17.6)
Missing data 14 3 1
ENT, ear, nose, and throat; SBP, spontaneous bacterial peritonitis.
Supplementary Table 1.Development of Infection and Death in Each of the Study Periods: at Baseline, on Treatment and
Post-Treatment
Variable treatment
arm
Baseline infection
Incident infection
On treatment Post-treatment
Prednisolone
(n ¼ 547)
No prednisolone
(n ¼ 545)
Prednisolone
(n ¼ 547)
No prednisolone
(n ¼ 545)
Prednisolone
(n ¼ 463)
No prednisolone
(n ¼ 447)
Deaths NA NA 76 (14) 98 (18) 145 (31) 141 (32)
Patients developing
an infection
64 (12) 71 (13) 127 (23) 124 (23) 56 (12) 33 (7)
Patients developing
infection at >1 site
2 (0.4) 4 (0.7) 8 (2) 10 (2) 6 (1) 4 (0.9)
Patients developing
>1 infection
0 0 16 (3) 12 (2) 0 0
NOTE. Values are n (%). Subgroups of patients developing more than 1 infection or at more than 1 site are shown.
NA, not applicable.
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Supplementary Table 3.Full Breakdown of Organisms Isolated From Patients Presenting With or Developing Infection, by
Relation in Terms of Timing to the Treatment Period
Organism Baseline
Incident infection
On treatment Post-treatment
Gram-negative bacilli, n (%) 23 (57.5) 45 (42.9) 19 (67.9)
Campylobacter spp, n 0 1
Coliforms (NOS), n 5 4 1
Enterobacter spp, n 0 1
Enterobacter cloacae, n 1 1
Escherichia coli, n 12 25 8
Fusobacterium nucleatum, n 0 0 1
Klebsiella spp, n 1 0 1
Klebsiella pneumoniae, n 2 7 4
Pseudomonas spp, n 0 2
Serratia marcescens, n 0 1 1
Unknown, n 2 3 3
Gram negative coccus, n (%) 0 2 (1.9) 0
Moraxella catarrhalis, n 0 1
Unknown, n 0 1
Gram positive bacilli, n (%) 2 (5) 7 (6.7) 3 (10.7)
Clostridium difficile, n 2 6 3
Unknown, n 0 1
Gram positive coccus, n (%) 11 (27.5) 44 (41.9) 5 (17.9)
Enterococcus spp, n 2 9 1
Enterococcus faecalis, n 1 1
Enterococcus faecium, n 0 2
Gemella spp, n 0 1
Micrococcus spp, n 0 1
Staphylococcus spp, n 2 6 1
Staphylococcus aureus, n 1 7 3
Staphylococcus epidermidis, n 0 1
Staphylococcus warneri, n 0 1
Streptococcus spp, n 2 9
Streptococcus anginosus, n 1 0
Streptococcus gordonii, n 1 0
Streptococcus mitis, n 0 1
Streptococcus pneumoniae, n 1 1
Streptococcus viridans, n 0 1
Unknown, n 0 3
Mixed NOS, n (%) 2 (5) 2 (1.9) 0
Fungus, n (%) 2 (5) 4 (3.8) 1 (3.6)
Candida spp, n 1 0
Candida albicans, n 0 4 1
Unknown, n 1 0
Viral, n (%) 0 1 (1.0) 0
Norovirus, n 0 1
NOS, not otherwise specified.
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Supplementary Table 5.Area Under Receiver Operating
Curve Comparison Between
Bacterial DNA and White Blood Cell
Count
Parameter AUROC P value 95% CI
bDNA 0.704 .003 .57.83
White blood cell count 0.577 .265 .44.72
AUROC, area under receiver operating curve.
Supplementary Table 6.Effect of Smoking on Risk of
Developing Incident Infection
Term OR (95% CI) P value
Smoking (never) Reference .14
Smoking (current) .68 (.461.01) .06
Smoking (prior) .91 (.581.41) .67
Prednisolone 1.23 (.881.73) .23
Supplementary Table 4.Baseline Characteristics of Bacterial
DNA Cohort, by Day 7 Infection
Status
Variable
No early-onset
infection (n ¼ 638)
Early-onset
infection (n ¼ 93)
Age, y 49 (4257) 50 (4158)
Sex, male, n (%) 415 (57) 54 (58)
Alcohol consumption,
U/wk
126 (81206) 140 (98213)
Prednisolone, n (%) 326 (51) 40 (43)
Systolic blood
pressure, mm Hg
111 (103121) 110 (100123)
Diastolic blood
pressure, mm Hg
68 (6075) 65 (6072)
Pulse, beats/min 90 (8098) 92 (80101)
Temperature, C 36.8 (36.537.1) 36.8 (36.537.0)
Haemoglobin, g/L 108 (95121) 100 (90114)
White blood cell count,
103 per mm3
8.7 (6.012.3) 10.3 (7.314.7)
Neutrophils, 103 per
mm3
5.9 (4.09.3) 7.9 (5.412.0)
International
normalised ratio
1.7 (1.52.0) 1.9 (1.62.2)
Albumin, g/dL 24 (2129) 25 (2129)
Bilirubin, mg/dL 16.5 (10.024.3) 17.3 (11.724.6)
Alanine transaminase,
IU/L
44 (3164) 41 (2666)
Aspartate
transaminase, IU/L
128 (90176) 120 (86155)
Sodium, mmol/L 134 (130137) 133 (129136)
Urea, mmol/L 3.2 (2.25.1) 3.7 (2.35.6)
Creatinine, mg/dL 0.72 (0.600.95) 0.74 (0.581.09)
Discriminant function 54 (4271) 61 (4681)
Model for End-Stage
Liver Disease
23 (2126) 24 (2229)
Pretreatment
antibiotics,a n (%)
156/638 (24) 39/93 (42)
bDNA, pg/mL 9.2 (3.223.8) 12.3 (5.639.4)
NOTE. Data are median (interquartile range) unless other
indicated.
MELD, Model for End-Stage Liver Disease.
aPretreatment antibiotics defined as intravenous antibiotics
commenced within 5 days prior to starting trial therapy.
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